Experimental cancer treatments

SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast

Retrieved on: 
Friday, December 11, 2020
Branches of biology, Cytokines, Granulocyte-macrophage colony-stimulating factor, Clinical medicine, Medicine, Cancer vaccines, Virotherapy, Experimental cancer treatments

This investigator-sponsored trial randomized patients to receive, prior to surgery, either GM-CSF followed by NPS two weeks later or GM-CSF alone.

Key Points: 
  • This investigator-sponsored trial randomized patients to receive, prior to surgery, either GM-CSF followed by NPS two weeks later or GM-CSF alone.
  • The updated data, based on a 6-month follow-up, demonstrate that CD8+ T-cell responses persist long-term post-NPS treatment, with treated patients retaining and modestly enhancing their antigen-specific immune response.
  • Further data from additional analyses of select histologic and molecular biomarkers will be presented in a future scientific meeting.
  • The VADIS data will be presented today, December 11, at the Virtual 2020 Annual San Antonio Breast Cancer Symposium (SABCS)
    Title: Vadis trial: phase II trial of Nelipepimut-S peptide vaccine in women with DCIS of the breast.

CG Oncology Closes $47 Million Series D Financing

Retrieved on: 
Thursday, December 10, 2020
Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Virotherapy, Medicine, Oncology, Kissei, Immunotherapy, Oncolytic virus, Experimental cancer treatments, Health care, Biotechnology, Akseli Hemminki

CG Oncology, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 million Series D preferred stock financing led by new investor Kissei Pharmaceutical Co., Ltd., with participation from existing investors ORI Healthcare Fund, Camford Capital and Perseverance Capital Management.

Key Points: 
  • CG Oncology, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 million Series D preferred stock financing led by new investor Kissei Pharmaceutical Co., Ltd., with participation from existing investors ORI Healthcare Fund, Camford Capital and Perseverance Capital Management.
  • We are excited to close our Series D round of funding, which will allow us to advance our late-stage pipeline, as new treatment options are desperately needed for patients with bladder cancer, said Arthur Kuan, CEO of CG Oncology.
  • We look forward to working closely with CG Oncology to address the significant unmet medical needs in oncology with this innovative therapy.
  • CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.

OncoMyx Announces Assignment of Foundational Technology and Intellectual Property Portfolio for Oncolytic Myxoma Virus Technology

Retrieved on: 
Monday, December 7, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Animal virology, Health sciences, Clinical medicine, Experimental cancer treatments, Biotechnology, Chordopoxvirinae, Myxoma virus, Myxomatosis, Virotherapy, Oncolytic virus, Virus, Myxoma Virotherapy for the Treatment of Cancer, OncoMyx Therapeutics

The assignment of this technology and intellectual property to OncoMyx further reinforces our IP portfolio protecting our use of myxoma virus and our pipeline of myxoma virotherapies for the treatment of cancer, said Steve Potts, Ph.D., MBA, cofounder and chief executive officer of OncoMyx.

Key Points: 
  • The assignment of this technology and intellectual property to OncoMyx further reinforces our IP portfolio protecting our use of myxoma virus and our pipeline of myxoma virotherapies for the treatment of cancer, said Steve Potts, Ph.D., MBA, cofounder and chief executive officer of OncoMyx.
  • I am pleased that OncoMyx has been assigned the patent rights associated with the pioneering myxoma research that was done at Western, as the myxoma virus is unique as a technology platform to build oncolytic immunotherapies.
  • Because myxoma virus is not pathogenic to humans, myxoma virotherapy does not have to overcome pre-existing immunity.
  • OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer.

Turnstone Biologics Announces First Patients Enrolled in Phase 1/2 Clinical Trial Evaluating RIVAL-01 For the Treatment of Solid Tumors

Retrieved on: 
Tuesday, December 1, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, ClinicalTrials.gov, Medical research, Experimental cancer treatments, Medicine, Cancer research, Prodrugs

The enrollment of the first patients into our Phase 1/2a trial is a key milestone for Turnstone and meaningfully advances our aim of transforming the treatment paradigm for people with cancer, said Mike Burgess, Ph.D., President of R&D, Turnstone.

Key Points: 
  • The enrollment of the first patients into our Phase 1/2a trial is a key milestone for Turnstone and meaningfully advances our aim of transforming the treatment paradigm for people with cancer, said Mike Burgess, Ph.D., President of R&D, Turnstone.
  • The transgenes are designed to be expressed when the vaccinia virus, delivered either intratumorally or intravenously, enters and replicates in cancer cells.
  • Patients are currently enrolling in Phase 1 dose escalation, which will be followed by an expansion phase in specified tumor types in the Phase 2a portion of the trial.
  • Additional information about the trial, including eligibility criteria and a list of clinical trial sites, can be found at https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04301011).

CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Muscle-Invasive Bladder Cancer

Retrieved on: 
Thursday, November 12, 2020
Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Drugs, Medicine, Virotherapy, Breakthrough therapy, Experimental cancer treatments, Antineoplastic drugs, Monoclonal antibodies, Oncolytic virus, Oncology, Nivolumab, Bladder cancer, Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Drugs, Medicine, Virotherapy, Breakthrough therapy, Experimental cancer treatments, Antineoplastic drugs, Monoclonal antibodies, Oncolytic virus, Oncology, Nivolumab, Bladder cancer, CG0070, CG Oncology

announced today that the first patient has been treated in an investigator-initiated Phase 1b study evaluating the safety and efficacy of CG0070 in combination with OPDIVO (nivolumab), as a neoadjuvant immunotherapy for Muscle-Invasive Bladder Cancer (MIBC) in cisplatin-ineligible patients.

Key Points: 
  • announced today that the first patient has been treated in an investigator-initiated Phase 1b study evaluating the safety and efficacy of CG0070 in combination with OPDIVO (nivolumab), as a neoadjuvant immunotherapy for Muscle-Invasive Bladder Cancer (MIBC) in cisplatin-ineligible patients.
  • CG0070 dosing of the first patient in our Phase 1b combination study with anti-PD1 antibody OPDIVO represents a key milestone for our oncolytic immunotherapy clinical program, said Arthur Kuan, Chief Executive Officer at CG Oncology.
  • We are excited to advance our investigational oncolytic immunotherapy CG0070 to improve the lives of patients with MIBC.
  • CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.

Replimune to Participate at the SVB Leerink Oncology 1x1 Day

Retrieved on: 
Thursday, November 12, 2020
Experimental cancer treatments, Clinical medicine, Virotherapy, Oncolytic virus, Cancer immunotherapy, Medicine, Biotechnology, Medical specialties, Adenoviridae

WOBURN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members of its senior management team will host investor meetings at the at the SVB Leerink Oncology 1x1 Day being held on Thursday, November 19, 2020.

Key Points: 
  • WOBURN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members of its senior management team will host investor meetings at the at the SVB Leerink Oncology 1x1 Day being held on Thursday, November 19, 2020.
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.
  • Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.
  • Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action.For more information, please visit www.replimune.com .

Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting

Retrieved on: 
Thursday, November 12, 2020
Immune system, Branches of biology, Medical specialties, Lymphocytes, Biology, Experimental cancer treatments, Natural killer cell, Oncolytic virus, Virotherapy

Natural killer (NK) cells are innate immune cells with natural cytotoxicity towards both tumor cells and virus infected cells.

Key Points: 
  • Natural killer (NK) cells are innate immune cells with natural cytotoxicity towards both tumor cells and virus infected cells.
  • This study explored the combination of the two investigational therapies, oncolytic virotherapy and adoptive PM21-NK cell therapy, enhancing the overall killing of lung cancer cells in both 2-dimensional (2D) and 3-dimensional (3D) tumor cultures.
  • All SITC posters are on display from 8 a.m. on November 9 until the virtual poster hall closes on December 31, 2020.
  • Kiadis Pharma N.V. (Kiadis) is een Nederlands beursgenoteerd biotechbedrijf in de klinische fase dat nieuwe geneesmiddelen ontwikkelt tegen ernstige ziekten.

Amphivena Presents Clinical Update and Translational Data of AMV564 in Solid Tumor Patients at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Monday, November 9, 2020
Clinical medicine, Cancer, Medicine, Oncology, Gynaecological cancer, Gynaecology, Ovarian cancer, Breakthrough therapy, Experimental cancer treatments, Evofosfamide, Eftilagimod alpha

The Phase 1 dose escalation study (NCT04128423) enrolled 16 advanced solid tumor patients into the monotherapy cohort at the time of data cut off.

Key Points: 
  • The Phase 1 dose escalation study (NCT04128423) enrolled 16 advanced solid tumor patients into the monotherapy cohort at the time of data cut off.
  • The majority (62.5%) of patients received 3 or more lines of prior therapy while 31% of patients received prior checkpoint-inhibitor therapy.
  • Based on the safety, PK profile and clinical activity including a confirmed RECIST complete response in an ovarian cancer patient, AMV564 will be further explored in selected solid tumor indications.
  • Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the Phase
    1 solid tumor trial of AMV564, a novel T-cell engager

OncoMyx Announces Presentation of Preclinical Efficacy Data of Novel Oncolytic Immunotherapy at SITC 2020

Retrieved on: 
Monday, November 9, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Medical specialties, Experimental cancer treatments, Biotechnology, Animal virology, Oncolytic virus, Cancer immunotherapy, Virotherapy, Immunotherapy, Myxoma, Society for Immunotherapy of Cancer

OncoMyx Therapeutics , a privately-held oncolytic immunotherapy company, announced the presentation of preclinical data at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting & Preconference Programs ( SITC 2020 ) taking place virtually November 9 to 14.

Key Points: 
  • OncoMyx Therapeutics , a privately-held oncolytic immunotherapy company, announced the presentation of preclinical data at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting & Preconference Programs ( SITC 2020 ) taking place virtually November 9 to 14.
  • The data are the first to demonstrate preclinical therapeutic efficacy of a multi-armed myxoma virotherapy for the treatment of cancer following intravenous (IV) or intratumoral (IT) delivery alone and in combination with immune checkpoint inhibitors.
  • Efficacy of Oncomyxs multi-armed myxoma virotherapy was seen in multiple subcutaneous and metastatic syngeneic tumor models, supporting a pan-tumor treatment approach.
  • The data are also extremely encouraging for IV delivery of our myxoma virotherapies, marking yet another desirable attribute that differentiates myxoma from other oncolytic viruses.

NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer

Retrieved on: 
Wednesday, November 4, 2020
Technology, Nanotechnology, Radiology, Practice Management, Pharmaceutical, Managed care, Oncology, Seniors, Hospitals, MEN, Biotechnology, Science, Other Science, Consumer, Research, Health, Cancer, Histopathology, Prostate cancer, Oncology, Clinical medicine, Medicine, Experimental cancer treatments, Virotherapy, Nanobiotix

NanOlogy LLC , a clinical-stage oncology company advancing intratumoral therapy for solid tumors, has enrolled the first patient in a Phase 2 clinical trial of NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection for local prostate cancer.

Key Points: 
  • NanOlogy LLC , a clinical-stage oncology company advancing intratumoral therapy for solid tumors, has enrolled the first patient in a Phase 2 clinical trial of NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection for local prostate cancer.
  • Craig G. Rogers, MD (Henry Ford Cancer Institute) , a clinical investigator for the Phase 2 trial, commented: NanoPac completed a first-in-human clinical safety trial in 2019.
  • In this innovative second trial, we will be evaluating both safety and efficacy of multiple intratumoral injections of NanoPac in patients with prostate cancer.
  • In addition to prostate cancer, NanOlogy clinical programs are advancing in other genitourinary cancers, as well as gastrointestinal, peritoneal, lung, and dermal cancers.